EvogeneEVGN
About: Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules and genetic elements as the core components for such products. It holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment followed by Industry.
Employees: 143
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 14 [Q3] → 15 (+1) [Q4]
4.38% less ownership
Funds ownership: 10.3% [Q3] → 5.92% (-4.38%) [Q4]
56% less capital invested
Capital invested by funds: $1.7M [Q3] → $752K (-$946K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for EVGN.
Financial journalist opinion
Based on 4 articles about EVGN published over the past 30 days
